Investigating new treatments for stimulant use disorders through PTPRD phosphatase inhibitors
PTPRD phosphatase inhibitors for stimulant use disorders
This study is looking at new ways to help people with stimulant use disorders by using a special type of compound to target a protein that may also be linked to conditions like Alzheimer's, with the hope of finding better treatments to improve their health.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10710969 on NIH RePORTER |
What this research studies
This research focuses on developing new drug treatments for stimulant use disorders by targeting the PTPRD phosphatase, which plays a role in the regulation of tau protein associated with neurodegenerative diseases like Alzheimer's. The approach involves using flavonols as positive modulators to enhance the activity of PTPRD, potentially reducing tau hyperphosphorylation and its associated pathologies. By understanding the genetic and environmental factors influencing these disorders, the research aims to create effective therapeutic strategies to improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with stimulant use disorders and those at risk for neurodegenerative diseases linked to tau pathology.
Not a fit: Patients who do not have stimulant use disorders or related neurodegenerative conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that help manage stimulant use disorders and related neurodegenerative conditions.
How similar studies have performed: Previous research has shown promise in targeting tau pathology with similar approaches, indicating potential for success in this novel strategy.
Where this research is happening
Baltimore, United States
- University of Maryland Baltimore — Baltimore, United States (Active)
Researchers
- Principal investigator: Uhl, George Richard — University of Maryland Baltimore
- Study coordinator: Uhl, George Richard
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.